Immedica - About the company
Immedica is an acquired company based in Stockholm (Sweden), founded in 2017. It operates as a Developer of therapeutic agents for multiple diseases. The company has 71 active competitors, including 18 funded and 29 that have exited. Its top competitors include companies like BeiGene, Moderna and AmerisourceBergen.
Company Details
Immedica is a developer of therapeutic agents for treating oncology, neurology, infectious diseases, ophthalmology, and inflammatory. The company has developed drugs (Arlevert and Vertisan) for treating Vertigo of various origins. The company has also developed drugs for corneal neovascularization.
- Website
- www.immedica.com/en
- Registered Address
- SUITE 4, 7TH FLOOR,50 BROADWAY,LONDON,UNITED KINGDOM,SW1H 0DB
Key Metrics
Founded Year
2017
Location
Stockholm, Sweden
Stage
Acquired
Investors
Ranked
29th among 71 active competitors
Employee Count
181 as on Sep 30, 2026
Investment & Acquisitions
Similar Companies
Exit Details
Acquired by KKR (Apr 23, 2024)
Legal entities associated with Immedica
Immedica is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Immedica Pharma Ab CIN: 0766.287.429 , Belgium, Active | Apr 01, 2021 | - | - | - |
IMMEDICA PHARMA UK LTD CIN: 11457556 , United Kingdom, Active | Jul 09, 2018 | - | 7 (As on Dec 31, 2024) |
Immedica's acquisition details
Click here to take a look at Immedica's acquisition in detail
Sign up to download Immedica's company profile
Immedica's funding and investors
Immedica is a funded company. Immedica has 1 institutional investor.
View details of Immedica's funding rounds and investors
Immedica's founders and board of directors
Founder? Claim ProfileImmedica's employee count trend
Immedica has 181 employees as of Sep 26. Here is Immedica's employee count trend over the years:
Uncover Immedica's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Immedica's Competitors and alternates
Top competitors of Immedica include BeiGene, Moderna and AmerisourceBergen. Here is the list of Top 10 competitors of Immedica, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
2nd |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 72/100 | |
3rd | AmerisourceBergen 1985, Chesterbrook (United States), Public | Drug Corporation | - | 68/100 | |
4th | Tesaro 2010, Waltham (United States), Acquired | Global biopharma innovating medicines in respiratory, immunology, oncology, HIV, and infectious diseases | $161M | 66/100 | |
5th | Developer of small molecule drugs for immunology and oncology | $136M | 61/100 | ||
6th | Asgard Therapeutics 2017, Lund (Sweden), Series A | Developer of cancer immunotherapeutic solutions based on direct cell reprogramming | $39.8M | 60/100 | |
7th |  Daiichi Sankyo 2005, Chuo City (Japan), Public | Developer of drugs to address diverse medical needs | - | 59/100 | |
8th | Developer of antibody mimetic and protein based drug for the treatment of multiple diseases | $43.3M | 58/100 | ||
9th | Deevloper of personalized immunotherapeutics for oncology, autoimmune and inflammatory diseases | $166M | 57/100 | ||
10th | Alligator Bioscience 2001, Lund (Sweden), Public | Developer of antibody-based immunotherapies for the treatment of cancer | $10M | 57/100 | |
29th | Developer of therapeutic agents for multiple diseases | - | 41/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Immedica's competitors? Click here to see the top ones
Immedica's Investments and acquisitions
Immedica has acquired 2 companies including Neurocrine and Marinus Pharma. Immedica has not made any investments as of now.Reports related to Immedica
Here is the latest report on Immedica's sector:
News related to Immedica
Filter this listMedia has covered Immedica for a total of 21 events in the last 1 year, 5 of them have been about company updates.
•
•
Zepzelca Approved in Kuwait as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung CancerCision•Sep 04, 2026•Immedica
•
•
Qatar Approves Zepzelca Plus Atezolizumab as First-Line Maintenance for Extensive-Stage Small Cell Lung CancerCision•Aug 03, 2026•PharmaMar, Immedica
•
Immedica receives UAE marketing authorization for Ztalmy® for CDKL5 deficiency disorderCision•Jun 23, 2026•Immedica
•
Immedica's LOARGYS® Approved in Canada for Arginase 1 Deficiency (ARG1-D)Cision•Jun 01, 2026•Immedica
•
Zepzelca Approved by European Commission for Extensive-Stage Small Cell Lung CancerCision•Jun 01, 2026•Immedica
•
•
Immedica Pharma AB: Efmody® Receives MHRA Approval for Adrenal Insufficiency in the UKCision•May 08, 2026•Immedica
•
Zepzelca® & atezolizumab receive positive CHMP opinion for small cell lung cancerCision•Mar 27, 2026•Immedica
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Immedica
Explore our recently published companies
- Healthcare Systems - Nagoya based, 2009 founded, Unfunded company
- Drones Magazine - Germany based, 2018 founded, Unfunded company
- Quality Life Services Home - Fairfield based, Unfunded company
- Red River Investments - United States based, 1999 founded, Unfunded company
- 22G Auto Sales - Brampton based, Unfunded company
- Sanalife Energy - 2023 founded, Unfunded company
